These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. [Pharmacokinetics of cyclosporine and its metabolites in patients undergoing kidney transplantation]. Silva Junior HT; Pereira AB; Ajzen H; Bueno V; Pestana JO Rev Assoc Med Bras (1992); 1994; 40(3):159-71. PubMed ID: 7787866 [TBL] [Abstract][Full Text] [Related]
63. Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. Perlík F; Masri MA; Rost M; Kamarád V Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):309-13. PubMed ID: 16601778 [TBL] [Abstract][Full Text] [Related]
65. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. John U; Ullrich S; Roskos M; Misselwitz J Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686 [TBL] [Abstract][Full Text] [Related]
66. Switchability of neoral and equoral according to Food and Drug Administration rules and regulations. Masri MA; Haberal M; Rizvi A; Stephan A; Bilgin N; Naqvi A; Barbari A; Kamel G; Zafar N; Emiroğlu R; Colak T; Manzoor K; Matha V; Kamarad V; Rost M; Rizk S; Hazime A; Perlik F Transplant Proc; 2005 Sep; 37(7):2988-93. PubMed ID: 16213282 [TBL] [Abstract][Full Text] [Related]
67. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Kuzuya T; Kobayashi T; Moriyama N; Nagasaka T; Yokoyama I; Uchida K; Nakao A; Nabeshima T Transplantation; 2003 Sep; 76(5):865-8. PubMed ID: 14501869 [TBL] [Abstract][Full Text] [Related]
68. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. del Mar Fernández De Gatta M; Santos-Buelga D; Domínguez-Gil A; García MJ Clin Pharmacokinet; 2002; 41(2):115-35. PubMed ID: 11888332 [TBL] [Abstract][Full Text] [Related]
69. Pharmacokinetics of cyclosporine after renal transplant in children. Mochon M; Cooney G; Lum B; Caputo GC; Dunn S; Goldsmith B; Baluarte HJ; Polinsky MS; Kaiser BA J Clin Pharmacol; 1996 Jul; 36(7):580-6. PubMed ID: 8844439 [TBL] [Abstract][Full Text] [Related]
70. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Frassetto L; Baluom M; Jacobsen W; Christians U; Roland ME; Stock PG; Carlson L; Benet LZ Transplantation; 2005 Jul; 80(1):13-7. PubMed ID: 16003227 [TBL] [Abstract][Full Text] [Related]
71. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics. Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591 [TBL] [Abstract][Full Text] [Related]
72. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295 [TBL] [Abstract][Full Text] [Related]
73. Pharmacokinetics of cyclosporine as a function of energy--protein deficiency in children with chronic renal failure. Lares-Asseff I; Zaltzman S; Pérez Guillé MG; Camacho GA; Murguía T; López MC; Toledo AR; Zaltzman-Rudy AB; Cravioto J J Clin Pharmacol; 1997 Mar; 37(3):179-85. PubMed ID: 9089419 [TBL] [Abstract][Full Text] [Related]